Abstract
Somatic genetic abnormalities provide important diagnostic and prognostic information and are potential therapeutic targets in pediatric acute leukemias. In the clinical setting these genetic aberrations are typically detected by karyotype, fluorescence in situ hybridization (FISH), or chromosomal microarray (CMA) analyses. In recent years, large-scale genomic studies have revealed a spectrum of novel, clinically significant molecular variants in pediatric leukemias. We recently developed a comprehensive DNA- and RNA-based next generation sequencing (NGS) panel, OncoKidsSM, which was designed to detect diagnostic, prognostic, and therapeutic markers across the spectrum of pediatric malignancies, including leukemias.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
